HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gillette Mach3 shave system represents $750 mil. R&D, manufacturing capital investment.

This article was originally published in The Rose Sheet

Executive Summary

GILLETTE MACH3 DEVELOPMENT REPRESENTS OVER $750 MIL. INVESTMENT in manufacturing capital and research and development, the company said. In addition to R&D costs, the figure includes the expense of reconfiguring manufacturing facilities, purchasing new equipment and training employees to produce the three-bladed wet shaving system, which Gillette calls the "most important new product" in its almost 100-year history. The company has filed over 35 patents for Mach3 to protect its investment.

You may also be interested in...



Gillette Mach 3 Turbo Offers Innovation At Premium Price, Toiletries Tie In

Gillette will unveil its first joint marketing campaign featuring the new Mach 3 Turbo razor and the reformulated and repackaged Gillette Series men's grooming line, the Boston firm announced during a press event Oct. 30

Gillette Mach 3 Turbo Offers Innovation At Premium Price, Toiletries Tie In

Gillette will unveil its first joint marketing campaign featuring the new Mach 3 Turbo razor and the reformulated and repackaged Gillette Series men's grooming line, the Boston firm announced during a press event Oct. 30

Gillette Mach3 Sister System Backed By $40 Mil. Marketing Spend

Gillette plans to spend more than $40 mil. on marketing for its much-anticipated women's triple blade shave system during the product's first year on the market, according to the company.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel